Year Two of This Alport Syndrome Trial Concludes with Encouraging Findings
source: pixabay.com

Year Two of This Alport Syndrome Trial Concludes with Encouraging Findings

According to a story from GlobeNewswire, the biopharmaceutical company Reata Pharmaceuticals, Inc., recently announced that year two of its phase 3 clinical trial has been completed. This trial is testing…

Continue Reading Year Two of This Alport Syndrome Trial Concludes with Encouraging Findings
The Results of This Phase 3 Alport Syndrome Trial Look Promising
source

The Results of This Phase 3 Alport Syndrome Trial Look Promising

According to a story from Globe Newswire, the biopharmaceutical company Reata Pharmaceuticals, Inc., recently announced the results of a phase 3 clinical trial that was testing its experimental product candidate…

Continue Reading The Results of This Phase 3 Alport Syndrome Trial Look Promising

Could Stopping Using the Word “Rare” Increase the Rate of Diagnosis for Rare Disease Patients?

The Word "Rare" Unfortunately, many experts in rare disease believe the phrase "rare disease" may be harming the very population it describes. The Director of the National Center for Advancing…

Continue Reading Could Stopping Using the Word “Rare” Increase the Rate of Diagnosis for Rare Disease Patients?
Alport Syndrome Patients Met With the FDA About Drug Development
source: pixabay.com

Alport Syndrome Patients Met With the FDA About Drug Development

According to a story from PR Newswire, patients with Alport syndrome, supported by the National Kidney Foundation and the Alport Syndrome Foundation, were involved in a meeting with representatives from…

Continue Reading Alport Syndrome Patients Met With the FDA About Drug Development

Results From Studies of an Experimental Drug for Chronic Kidney Disease Have Been Announced

Results from two studies looking at the effects of an experimental drug (bardoxolone) on kidney function in patients with chronic kidney disease (CKD) have been released. One of the studies…

Continue Reading Results From Studies of an Experimental Drug for Chronic Kidney Disease Have Been Announced